Historique
![Treatment of hepatitis C in HIV-infected patients. Significant progress but not the final step [Editorial]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_18016.webp?v=1771272395)
Périodique
Treatment of hepatitis C in HIV-infected patients. Significant progress but not the final step [Editorial]
(Traitement de l'hépatite C chez des patients infectés par le VIH. Des progrès significatifs ont été faits, mais la dernière marche n'est pas atteinte)
Auteur(s) :
MANNS, M. P. ;
WEDEMEYER, H.
Année
2004
Page(s) :
2909-2913
Sous-type de document :
Editorial
Langue(s) :
Anglais
Refs biblio. :
45
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Note générale :
JAMA, 2004, 292(23), p. 2909-2913
Résumé :
In the modern era of highly active antiretroviral therapy (HAART), hepatitis C virus (HCV) has emerged as a major cause of morbidity and death in human immunodeficiency virus (HIV) infection. An estimated 15% to 30% of HIV-infected individuals are coinfected with HCV, representing 150 000 to 300 000 patients in the United States alone.The prevalence of anti-HCV antibodies in HIV-infected persons differs significantly according to the HIV-exposure risk category, ranging from less than 10% in homosexual men to more than 85% in injecting drug users. In the vast majority of immunocompetent nonHIV-infected persons, chronic hepatitis C usually takes a relatively mild course, leading to liver cirrhosis in 2% to 25% after 20 to 25 years depending on the individual risk factor profile. Liver-related death is only slightly more frequent in HCV-infected individuals. In contrast, hepatitis C may take a much more severe course in HIV-infected patients. (Extract of the publication)
Affiliation :
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany